Celiac Disease Clinical Trial
Official title:
Mechanisms Underlying Development of Barrett's Esophagus in Patients With Gluten Related Disorders
In a small group of people gluten, a storage protein commonly in wheat and other grains, can
cause gut inflammation and symptoms like diarrhea and abdominal pain. Gluten-related
disorders include celiac disease (CD) and non-celiac gluten sensitivity (NCGS) and are
treated by starting a gluten free diet (GFD). Patients with CD and NCGS also more commonly
experience esophageal reflux and damage to the lining of the esophagus. A potential
consequence of long-standing heartburn is Barrett's esophagus (BE), a major risk factor for
cancer of the esophagus.
This study aims to investigate the mechanism that leads to reflux and BE in those with gluten
related disorders, and to assess if a GFD is beneficial. We will study the upper gut function
and reflux activity in patients with BE both with and without a GRD disorder. Testing will
occur before and after a gluten free diet is instituted. The results will help inform health
care providers and patients about the connection between gluten-related disorders, reflux,
BE, and the role of GFD.
Status | Not yet recruiting |
Enrollment | 40 |
Est. completion date | December 30, 2018 |
Est. primary completion date | September 30, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Aged 18 years and over - Barrett's Esophagus diagnosis based on endoscopy and esophageal biopsies - Patients able to comply to the study procedures, according to the investigator's own judgment Exclusion Criteria: - Patients who have been on a gluten free diet within the last six months - History of bariatric surgery, fundoplication, or gastrectomy (partial or complete) - Connective tissue disease - Concurrent organic GI pathology other than benign polyps, haemorrhoids, lipomas, H. pylori infection, diverticulosis, and melanosis coli - Chronic treatment with high dose opioids - Alcohol or drug abuse - Pregnant or breastfeeding women. Women enrolling in the study will be advised to avoid pregnancy during the course of the study by using adequate birth control such as abstinence, oral contraceptive pill, barrier contraceptives (i.e condom). If a subject becomes pregnant she will be withdrawn from the study. - Concurrent systemic disease and/or laboratory abnormalities considered by investigators to be a risk or that could interfere with data collection |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
McMaster University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Ratio of non-acidic to acidic reflux events | Proportion of non-acid to acid reflux events as determined by pH-impedance | At study start and at one month after a gluten free diet | |
Secondary | Reflux disease questionnaire | 12 questions with six choices each. Results are added such that best score is 12 and worst score is 72. | At study start and one month after a gluten free diet | |
Secondary | Esophageal motility | Manometric findings of the upper and lower sphincters and esophageal body | At study start | |
Secondary | Upper gastrointestinal motility | Fluoroscopic findings of gastroduodenal motility | At study start | |
Secondary | Leeds short form questionnaire | Questionnaire for dyspepsia. Nine questions with five choices each. Only eight question scores are summed. Best score is 8 and worst score is 40. | At study start and one month after a gluten free diet | |
Secondary | Gastroesophageal reflux disease-health related quality of life instrument | 11 questions. Ten of them are summed with six choices each. The best score is 0 and the worst score is 50. | At study start and one month after a gluten free diet |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04349904 -
Near-Focus NBI Classification of Villous Atrophy in Suspected Coeliac Disease: International Development and Validation
|
||
Recruiting |
NCT05581628 -
FREQUENCY OF FIBROMYALGIA IN PATIENTS WITH CELIAC DISEASE
|
||
Completed |
NCT04593251 -
Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis
|
Phase 1 | |
Completed |
NCT05810441 -
Intestinal Transglutaminase Antibodies in Celiac Disease Diagnosis
|
||
Recruiting |
NCT05555446 -
Bovine Colostrum to Prevent Absorption of Gluten
|
Early Phase 1 | |
Completed |
NCT02754609 -
Hookworm Therapy for Coeliac Disease
|
Phase 1 | |
Terminated |
NCT01902368 -
Celiac Disease Screening
|
N/A | |
Completed |
NCT02472704 -
Lymphocytic Enteritis and Suspected Coeliac Disease: Gluten vs Placebo
|
N/A | |
Completed |
NCT02312349 -
Assessment of Gluten-Free Availability in Elaborated Food Stores in Three Neighbourhoods of Buenos Aires City
|
||
Completed |
NCT01172665 -
Celiac Disease Database
|
||
Completed |
NCT01100099 -
HLA-DQ2-gliadin Tetramer for Diagnosis of Celiac Disease
|
Phase 2/Phase 3 | |
Completed |
NCT00639444 -
Risk of Celiac Disease and Age at Gluten Introduction
|
N/A | |
Active, not recruiting |
NCT05425446 -
Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients
|
Phase 1 | |
Enrolling by invitation |
NCT02202681 -
Imaging the Duodenum Using an Optical Frequency Domain Imaging OFDI Capsule
|
N/A | |
Completed |
NCT00362856 -
Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects
|
Phase 2 | |
Terminated |
NCT03866538 -
Budesonide in Patients With Immune Mediated Enteropathies
|
Phase 4 | |
Recruiting |
NCT05135923 -
Glutenfree, Gut Microbiota and Metabolic Regulation
|
N/A | |
Completed |
NCT05052164 -
Improvement Of Physical And Physiological Parameters In Menopausal Or Post-Menopausal Celiac Women
|
N/A | |
Completed |
NCT03775499 -
Probiotic BL NCC 2705 and Gluten Sensitivity
|
N/A | |
Completed |
NCT03707730 -
A Randomized, Double-Blind, Placebo Controlled, Crossover Trial to Evaluate Safety and Efficacy of AGY in Celiac Disease
|
Phase 2 |